Catalys Pacific, LLC
An institutional investment manager in TOKYO. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 5, 2026. SEC CIK 2011385.
- Reported value$229.5m
- Positions2
Holdings: 2 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc.MLYS | COM | 603170101 | 213 | 92.9% | 7,903,838 | Unchanged | |
| Phathom Pharmaceuticals, Inc.PHAT | COM | 71722W107 | 16.2 | 7.1% | 1,493,854 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-090867 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.